MedPath

Tagged News

ImmunoPrecise's AI-Designed GLP-1 Peptides Outperform Semaglutide in Receptor Activation Studies

AIDrug Discovery
  • ImmunoPrecise Antibodies announced that its AI-designed GLP-1 receptor agonist peptides achieved comparable or superior receptor activation to Semaglutide in independent third-party in vitro studies.
  • Two lead peptide candidates outperformed or matched Semaglutide under controlled assay conditions, with sequences rationally engineered using the company's proprietary HYFT technology for improved stability and peptidase resistance.
  • The breakthrough validates IPA's LENSai platform and demonstrates that AI can generate functionally validated peptide drugs with potential for rapid expansion into adjacent therapeutic areas.
  • The company is now considering two preclinical development paths including injectable delivery studies and non-invasive delivery strategies such as transdermal patches and nucleic acid-based delivery systems.

Sensible Biotechnologies Achieves 90% Reduction in mRNA Optimization Time Using AI-Powered Platform

AI
  • Sensible Biotechnologies has reduced mRNA optimization cycles from 15 days to just one day using NVIDIA-powered AI technology, representing a more than 90% time reduction.
  • The company's cell-based platform produces mRNA therapeutics within living cells, creating pure and low-immunogenicity drug products that could unlock new therapeutic areas including cancer and rare diseases.
  • The AI-driven platform achieves over 11,000 simulation steps per second and reduces simulation runtimes from overnight to under an hour per sequence.
  • This breakthrough enables faster development of next-generation mRNA medicines by allowing rapid screening of multiple RNA candidates in parallel.

Juvena Therapeutics Partners with Eli Lilly in AI-Driven Muscle Health Drug Discovery Collaboration

AIDrug Discovery
  • Juvena Therapeutics has entered a global licensing and multi-target research collaboration with Eli Lilly to discover and develop drug candidates that improve muscle health and body composition.
  • The partnership will leverage JuvNET, the world's first fully integrated AI-enabled screening platform for mapping therapeutic potential of stem cell-secreted proteins.
  • Under the agreement, Juvena will receive upfront payment, equity investment, and potential milestone payments while granting Lilly exclusive licenses to identified lead candidates.
  • The collaboration aims to address obesity, which affects one in eight people globally, by combining Lilly's metabolic disease expertise with Juvena's AI platform and stem-cell protein library.

Ryght AI Secures $3M Seed Funding and Expands Academic Partnerships to Accelerate Clinical Trial Site Selection

AI
  • Ryght AI raised $3 million in seed funding led by Foothill Ventures to advance its AI-powered clinical trial platform that creates digital twins of over 100,000 research sites worldwide.
  • The company announced new partnerships with academic medical centers including Emory University, West Virginia University, and West Clinic, joining previously established collaborations with USC Keck School of Medicine and Medical College of Wisconsin.
  • Ryght AI's platform addresses critical industry inefficiencies where sponsors spend up to $50,000 activating a single site and $50,000-$500,000 enrolling each patient, with 55% of trials failing due to poor site feasibility.
  • The AI-driven solution reduces traditional feasibility timelines from several months to less than three weeks through automated workflows and real-time site performance data.

Sofinnova Partners and NVIDIA Launch AI Infrastructure Partnership to Accelerate European Life Sciences Innovation

AIDrug DiscoveryPrecision Medicine
  • Sofinnova Partners, a leading European life sciences venture capital firm, has partnered with NVIDIA to provide GPU credits and high-performance AI infrastructure to its portfolio companies through NVIDIA DGX Cloud Lepton.
  • Four promising European digital medicine startups—BioCorteX, Bioptimus, Cure51, and Latent Labs—are among the first cohort to gain access to NVIDIA's computational resources, enabling faster biological data processing and model development.
  • Cure51 demonstrated the partnership's potential by achieving up to 17x faster genomic processing and more than 2x cost savings using NVIDIA's GPU-accelerated genomics toolkit compared to traditional CPU methods.
  • The collaboration aims to position Europe at the forefront of AI-driven drug discovery by providing startups with computational power comparable to Silicon Valley tech giants in the $100B+ life sciences market.

EssilorLuxottica Acquires European Ophthalmology Network Optegra to Advance Med-Tech Strategy

AI
  • EssilorLuxottica has entered into an agreement to acquire Optegra Eye Health Care, a European ophthalmology platform operating over 70 facilities across five markets including the UK, Czech Republic, Poland, Slovakia, and the Netherlands.
  • The acquisition supports EssilorLuxottica's medical technology strategy expansion, combining comprehensive eye care with advanced diagnostics and AI-powered surgical treatments in a unified platform.
  • Optegra's network provides ophthalmic treatments including cataract surgery, glaucoma treatments, age-related macular degeneration therapies, and laser eye surgery with artificial intelligence integration in pre- and post-operative stages.
  • The transaction is expected to close in 2025 pending regulatory approvals and will enable EssilorLuxottica to leverage AI and big data capabilities for personalized patient care and detection of conditions ranging from neurodegenerative diseases to cardiovascular dysfunction.

Medable Launches AI-Powered Partner Program to Accelerate Clinical Trial Startup by 50%

AI
  • Medable has launched a Partner Program that provides contract research organizations with generative AI-driven electronic clinical outcome assessment build capabilities to reduce clinical trial timelines by at least 50%.
  • The program features Studio, an AI-powered tool for creating and reusing eCOA instruments, offering CROs flexible self-service, managed service, or hybrid support models.
  • The initiative aims to enable rapid trial-specific quote generation and pre-built digital studies for bid defense meetings, supporting Medable's vision of achieving one-day study startup.
  • Medable's digital clinical trials platform has been utilized in nearly 400 trials across 70 countries, demonstrating the company's established presence in clinical technology solutions.

IQVIA and NVIDIA Launch AI Orchestrator Agents to Accelerate Clinical Research and Drug Development

AI
  • IQVIA announced the launch of multiple AI orchestrator agents in collaboration with NVIDIA at GTC Paris, designed to manage and accelerate complex pharmaceutical development workflows for thousands of global customers.
  • The AI agents can reduce clinical trial start-up processes from 200 days and clinical data review from seven weeks to as little as two weeks through automated workflows and specialized sub-agents.
  • The orchestrator agents utilize NVIDIA NIM microservices and IQVIA's petabytes of healthcare data to streamline target identification, clinical site start-up, and drug commercialization processes.
  • The technology enables pharmaceutical companies to focus on decision-making rather than time-consuming administrative tasks while providing comprehensive market analysis in days instead of weeks.

Solvonis Therapeutics Launches AI-Powered CNS Drug Discovery Platform for Depression and Addiction

AIDrug Discovery
  • Solvonis Therapeutics has initiated an artificial intelligence-supported drug discovery programme targeting its proprietary central nervous system compound library acquired through the Awakn Life Sciences acquisition.
  • The AI platform will focus on data-driven asset prioritisation and structure-activity relationship analysis to accelerate identification of development candidates for depression and stimulant use disorders.
  • Under Professor David Nutt's scientific leadership, the programme complements Solvonis' existing clinical pipeline, which includes Phase 3 trials for alcohol use disorder affecting over 80 million people across the UK, US, and EU4.
  • The initiative represents a strategic expansion into earlier-stage innovation while maintaining focus on high-burden neuropsychiatric conditions with significant unmet medical need.

GenePoweRx Partners with MGI Tech to Advance AI-Powered Genomic Solutions for Personalized Medicine

AIPrecision Medicine
  • GenePoweRx, an Indian AI-driven personalized medicine startup, has formed a strategic co-marketing partnership with China-based MGI Tech to deliver AI-powered genomic solutions for predictive healthcare and precision medicine.
  • The collaboration integrates MGI's robust sequencing platforms with GenePoweRx's advanced bioinformatics and AI engine to provide rapid, accurate, and clinical-grade genomic services to individuals and institutions worldwide.
  • The partnership aims to democratize access to advanced healthcare technologies by embedding precision genomics into everyday medical decision-making and making personalized preventive healthcare more accessible and actionable.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.